Renal function changes in HCV-infected patients with chronic kidney disease during and after treatment with direct antiviral agents
- 28 July 2017
- journal article
- letter
- Published by Elsevier in Digestive and Liver Disease
- Vol. 49 (10) , 1166-1169
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experienceJournal of Viral Hepatitis, 2016
- Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal DiseaseGastroenterology, 2016
- Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 studyThe Lancet, 2015
- Extrahepatic manifestations of chronic hepatitis C virus infectionTherapeutic Advances in Infectious Disease, 2015
- Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veteransHepatology, 2014
- Hepatitis C virus associated glomerulopathiesWorld Journal of Gastroenterology, 2014
- Hepatitis C Virus Infection and Kidney DiseaseClinical Journal of the American Society of Nephrology, 2012
- Hepatitis C Infection and Chronic Renal DiseasesClinical Journal of the American Society of Nephrology, 2009
- Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGNAmerican Journal of Kidney Diseases, 2004
- Hepatitis C virus–related cryoglobulinemic glomerulonephritis: Long-term remission after antiviral therapyKidney International, 2003